- The share
- Press releases
- Financial calendar
- Financial reports
- Prospectus and material offerings
- Financial presentations
- Corporate governance
- Analyst Coverage
- CODE OF CONDUCT
- Thank you
XVIVO Perfusion adds two more XPS™ installations in the U.S.
California has the highest population count of all states in the US and is ranked among the top five regarding the number of lung transplants performed in the US. Virginia is the twelfth most populated state in the US and has seen a growing number of lung transplants in the recent years.
"We are looking forward to working with XVIVO to advance the success of lung transplantation at UVA by combining our excellent outcomes with innovative technology to increase the number of available lungs to patients on our transplant list" says Christine Lau, MD, Associate Professor of Surgery, Univ. of Virginia.
“The lung transplant program at Cedars-Sinai Medical Center in Los Angeles is very excited and eager to begin participation in XVIVO’s ex-vivo lung perfusion system protocol. Each year hundreds of potentially transplantable lungs from extended criteria donors nationwide are needlessly wasted due to marginal quality thus increasing the waiting time for patients on the lung transplant wait list and increasing their risk of death while waiting. With the use of EVLP we hope to broaden the donor pool for our wait-listed patients so that they can receive a lifesaving lung transplant before it becomes too late for them”, says George E. Chaux, Medical Director, Lung and Heart-Lung Transplant Program, Cedars-Sinai Medical Center.
XVIVO Perfusion’s XPS™ and STEEN Solution™ are the only approved products in the USA for evaluation of marginal lungs before lung transplantation. The products enable more lungs to be used for transplantation, which means that more patients with severe lung disease are given a higher quality and longer life. Leading clinics in the USA have obtained good clinical results when using XPS™.
August 3, 2015
XVIVO Perfusion AB (publ)
For further information please contact:
Christoffer Rosenblad, CFO, +46 31 788 21 59, email@example.com
For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com
The information was submitted for publication on August 3, 2015 at 8:30 a.m.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.